Navigation Links


Varioskan at Biology News

Varioskan at Biology Products

Varioskan (100-240 V) from Thermo Scientific

Description:Varioskan is a high performance spectral scanning multimode reader with built-in dispenser and incubator. With the advanced SkanIt Software it offers superior flexibility and reliability for drug discovery assay development. Varioskan provides unlimited wavelength selection for fluorescence intensity, time-resolved fluorescence and photometric assays and a dispenser for optimization of kinetic as...
Company:Thermo Scientific

Varioskan with one dispenser (100-240 V) from Thermo Scientific

Description:Varioskan is a high performance spectral scanning multimode reader with built-in dispenser and incubator. With the advanced SkanIt Software it offers superior flexibility and reliability for drug discovery assay development. Varioskan provides unlimited wavelength selection for fluorescence intensity, time-resolved fluorescence and photometric assays and a dispenser for optimization of kinetic as...
Company:Thermo Scientific

SkanIt Software for Varioskan, Drug Discovery Edition from Thermo Scientific

Description:SkanIt™ Software is the ultimate tool for both microplate reader control and data handling. There are two editions of SkanIt Software available; a Research Edition for scientists working in life science research, and a Drug Discovery Edition offering features needed for compliance with FDA's 21 CFR Part 11, for the drug discovery industry....
Company:Thermo Scientific
Varioskan at Biology Technology
Varioskan at Medicine News
Varioskan at Medicine Products
Varioskan at Medicine Technology
Other TagsWesternWesternWesternWesternWestern
(Date:10/11/2008)... Barnett International, a... has announced the release of The Form FDA 1572: A...s, and Monitors. Designed for clinical investigato...y affairs professionals, and others involved in th... reference guide to address the Form FDA 1572-Stat...
(Date:10/10/2008)... PACO Communications Named Agency ...gian American Hospital has just,announced the laun...signed,to build awareness of its long-standing com... and care through its Labor and Delivery, Special ... rolled out in Chicago with a focus on public rela...
(Date:10/10/2008)...1 in 6 likely to develop some form of disease by 2...FRIDAY, Oct. 10 (HealthDay News) -- Liver transpla... the general population, say researchers in Finlan...ssue of Liver Transplantation , researchers inves...er transplant recipients from Helsinki University ...
(Date:10/10/2008)... MONTVALE, N.J., Oct. 10 /PRNewswire-FirstCall/...unces that it has appointed William,(Bill) Federic...ard to five,members., Mr. Federici joined West Ph...Financial Officer in August of 2003. Under his fin...have grown to more than $1.0 billion from,$300 mil...
Breaking Medicine News(10 mins):Health News:Barnett Releases Reference Guide on Form FDA 1572--Statement of Investigator 2Health News:Barnett Releases Reference Guide on Form FDA 1572--Statement of Investigator 3Health News:Norwegian American Hospital Launches Awareness Campaign Targeting Hispanic, African-American and General-Market Moms 2Health News:Norwegian American Hospital Launches Awareness Campaign Targeting Hispanic, African-American and General-Market Moms 3Health News:Liver Transplant Patients at Higher Cancer Risk 2Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 2Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 3
(Date:10/10/2008)...Haven, Conn. Yale scientists have created nanowir...ronics that are both sensitive and specific enough...ion, according to a report in Nano Letters . , ...ly specific antigens signatures of bacteria, viru... are activated, they produce acid, and generate a ...
(Date:10/9/2008)...NTA CLARA, Calif., Oct. 9 /PRNewswire-FirstCall/ -...ading developer of human interface,solutions for m... devices,announced today that it will report fina... on Thursday, October 23, 2008 after the close of ...erence call for analysts and,investors at 2:00 p.m...
(Date:10/9/2008)...It,s hard being a mussel: you have to worry about ...ention an environment that can change your body te...s. , "It,s one of the most variable habitats on ... can spend part of the day bathed in cool Pacific ...rnia sun." , Gracey led the first real-time mole...
(Date:10/9/2008)...National Institute of Allergy and Infectious Disea...alth (NIH), will award five-year contracts estimat... in Systems Biology for Infectious Disease Researc...h facility will apply novel techniques to study di...ome (SARS), tuberculosis and influenza. , System...
Breaking Biology News(10 mins):Sensitive nanowire disease detectors made by Yale scientists 2Synaptics to Report First Quarter Results on October 23 2Brainy genes, not brawn, key to success on mussel beach 2Brainy genes, not brawn, key to success on mussel beach 3New Systems Biology Awards enable detailed study of microbes 2Viant Appoints Keith Vangeison as Executive Vice President of Network Development 6675 1Viant Appoints Keith Vangeison as Executive Vice President of Network Development 6675 2Study Finds a Lack of Health Insurance May Roadblock Some Diabetes Patients From Seeking Critical Treatment 6671 1Study Finds a Lack of Health Insurance May Roadblock Some Diabetes Patients From Seeking Critical Treatment 6671 2Marketing and Meeting Details 28M2D 29 Officially Launches an Innovative Life Sciences Marketing and Communications Company 6667 1Marketing and Meeting Details 28M2D 29 Officially Launches an Innovative Life Sciences Marketing and Communications Company 6667 2Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE 28R 29 28Irbesartan Hydrochlorothiazide 29 a 879 1Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE 28R 29 28Irbesartan Hydrochlorothiazide 29 a 879 2Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE 28R 29 28Irbesartan Hydrochlorothiazide 29 a 879 3Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE 28R 29 28Irbesartan Hydrochlorothiazide 29 a 879 4Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE 28R 29 28Irbesartan Hydrochlorothiazide 29 a 879 5Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE 28R 29 28Irbesartan Hydrochlorothiazide 29 a 879 6Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE 28R 29 28Irbesartan Hydrochlorothiazide 29 a 879 7
Other Contentsabortionabortionabortionabortioninevitableinevitableinevitableinevitablereflexesreflexesreflexesdistressdistressdistressbotulismbotulismbotulisminfarctinfarctinfarctinfantsinfantsinfantsinfantsinfantsinfantsinfantileinfantile